• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

作者信息

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani E M, Di Bona E, Cassibba V, Scattolin A M, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A

机构信息

1] UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy [2] USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy.

USC Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy.

出版信息

Blood Cancer J. 2014 Jul 11;4(7):e225. doi: 10.1038/bcj.2014.48.

DOI:10.1038/bcj.2014.48
PMID:25014772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4219445/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f9/4219445/5f7a28f2f1b2/bcj201448f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f9/4219445/5f7a28f2f1b2/bcj201448f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0f9/4219445/5f7a28f2f1b2/bcj201448f1.jpg

相似文献

1
Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.诱导后微小残留病的不同分子水平可能预测成人费城染色体阴性急性淋巴细胞白血病的造血干细胞移植结局。
Blood Cancer J. 2014 Jul 11;4(7):e225. doi: 10.1038/bcj.2014.48.
2
Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.基于微小残留病灶的成人费城阳性急性淋巴细胞白血病的低强度预处理与清髓性预处理的长期疗效比较。
Cancer. 2019 Mar 15;125(6):873-883. doi: 10.1002/cncr.31874. Epub 2018 Dec 6.
3
Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.微小残留病时代成人费城染色体阴性急性淋巴细胞白血病首次完全缓解时的造血干细胞移植。
Curr Oncol Rep. 2018 Mar 26;20(4):36. doi: 10.1007/s11912-018-0679-9.
4
Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".费城染色体阳性急性淋巴细胞白血病：我们仍需要异基因移植吗？正方观点。
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S10-S15. doi: 10.1016/j.clml.2017.03.296.
5
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.单倍体与同胞相合供者在成人急性淋巴细胞白血病造血干细胞移植中的结局：欧洲血液和骨髓移植学会急性白血病工作组的一项研究。
J Hematol Oncol. 2021 Apr 1;14(1):53. doi: 10.1186/s13045-021-01065-7.
6
Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.免疫球蛋白和T细胞受体基因高通量测序可定量急性淋巴细胞白血病中的微小残留病，并预测移植后复发和生存情况。
Biol Blood Marrow Transplant. 2014 Sep;20(9):1307-13. doi: 10.1016/j.bbmt.2014.04.018. Epub 2014 Apr 24.
7
The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia.异基因造血干细胞移植在急性淋巴细胞白血病患者治疗中的作用。
Curr Hematol Malig Rep. 2012 Jun;7(2):144-52. doi: 10.1007/s11899-012-0116-3.
8
Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.流式细胞术与 RQ-PCR 检测费城染色体阳性急性淋巴细胞白血病造血干细胞移植后微小残留病的比较分析。
Biol Blood Marrow Transplant. 2018 Sep;24(9):1936-1943. doi: 10.1016/j.bbmt.2018.03.015. Epub 2018 Mar 20.
9
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.在接受清髓性异基因移植的成人急性淋巴细胞白血病患者中可测量残留病：来自 EBMT 急性白血病工作组的 2780 例患者的回顾性登记研究。
J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.
10
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.异基因造血细胞移植的非清髓预处理治疗高危急性淋巴细胞白血病。
Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.

引用本文的文献

1
Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病临床试验中主要终点和疗效定义需要达成共识。
Blood Adv. 2024 Aug 13;8(15):4234-4238. doi: 10.1182/bloodadvances.2023010449.
2
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.四十余年来，MD 安德森对急性淋巴细胞白血病的研究与治疗的进展
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.
3
MRD in ALL: Optimization and Innovations.ALL 中的微小残留病灶：优化与创新。

本文引用的文献

1
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.根据强化治疗后流式细胞术评估的早期细胞形态学反应和微小残留病对青少年和成人高危费城染色体阴性急性淋巴细胞白血病的治疗：PETHEMA ALL-AR-03 试验的最终结果。
J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.
2
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.依妥珠单抗奥滨尤妥珠单抗治疗难治性/复发急性淋巴细胞白血病的疗效。
Cancer. 2013 Aug 1;119(15):2728-36. doi: 10.1002/cncr.28136. Epub 2013 Apr 30.
3
Curr Hematol Malig Rep. 2022 Aug;17(4):69-81. doi: 10.1007/s11899-022-00664-6. Epub 2022 May 26.
4
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?成人 Ph/BCR-ABL 阴性 ALL 中的微小残留病灶：如何最好地清除？
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):718-725. doi: 10.1182/hematology.2021000224.
5
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods.低通量和高通量方法检测成人急性淋巴细胞白血病微小残留病的预后价值。
Blood Adv. 2022 May 24;6(10):3006-3010. doi: 10.1182/bloodadvances.2021006727.
6
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.成人患者 18-65 岁急性淋巴细胞白血病的更新风险导向策略：NILG ALL 10/07。
Blood Cancer J. 2020 Nov 13;10(11):119. doi: 10.1038/s41408-020-00383-2.
7
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.Blinatumomab 对比成人 B 细胞前体急性淋巴细胞白血病微小残留病灶的历史标准治疗。
Eur J Haematol. 2020 Apr;104(4):299-309. doi: 10.1111/ejh.13375. Epub 2020 Jan 24.
8
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.急性淋巴细胞白血病中的微小残留病：技术与临床进展
Front Oncol. 2019 Aug 7;9:726. doi: 10.3389/fonc.2019.00726. eCollection 2019.
9
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.一项系统性文献回顾和荟萃分析，探讨微小残留病作为成人 B 细胞急性淋巴细胞白血病的预后指标。
Haematologica. 2019 Oct;104(10):2028-2039. doi: 10.3324/haematol.2018.201053. Epub 2019 Mar 19.
10
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.拿下 ALL 的“必杀技”：blinatumomab 获批 MRD 阳性 ALL。
Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.CD19 靶向 T 细胞可迅速诱导化疗耐药的成人急性淋巴细胞白血病患者达到分子缓解。
Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.
4
Has MRD monitoring superseded other prognostic factors in adult ALL?MRD 监测是否已经取代了成人 ALL 的其他预后因素？
Blood. 2012 Nov 29;120(23):4470-81. doi: 10.1182/blood-2012-06-379040. Epub 2012 Oct 2.
5
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.在一项blinatumomab 治疗 B 系 ALL 患者微小残留病的 2 期研究中，血液学无复发生存的长期随访结果。
Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.
6
Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.移植时微小残留病对急性白血病的预后和治疗意义。
Bone Marrow Transplant. 2013 May;48(5):630-41. doi: 10.1038/bmt.2012.139. Epub 2012 Jul 23.
7
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.造血细胞移植前可检测到的微小残留病具有预后意义，但不能排除高危白血病患儿的治愈可能。
Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19.
8
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.急性淋巴细胞白血病伴分子学复发的成年患者预后不良，是干细胞移植和靶向治疗的候选人群。
Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22.
9
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.高剂量单药奈拉滨治疗复发 T 淋巴细胞白血病/淋巴瘤具有较高的活性，可作为后续干细胞移植的治愈选择。
Blood. 2011 Sep 29;118(13):3504-11. doi: 10.1182/blood-2011-01-329441. Epub 2011 Jun 28.
10
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.在干细胞移植前根据微小残留病水平对高危儿科急性淋巴细胞白血病患者进行抢先性同种免疫干预。
Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10.